Actuate Therapeutics Inc
- ACTU
- NASDAQ
- Biotechnology
- Oncology Biotech
- Kinase Inhibitors
$0.60
Today +21.02%Quote Oct 16, 2026, 08:00 PM UTC
−39.21%over the last month
Max drawdown −56.4%From 1-month high −39.2%3 months −56.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$14.5M
Quote Oct 16
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$21.00
+3371.1% from here
Floor
$0.60
0.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ACTUPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
12